Clinical trial NCT05746793: At High-risk for Pre-eclampsia After Assisted Reproductive Technology
Official title: At High-risk for Pre-eclampsia After Assisted Reproductive Technology
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Pre-Eclampsia
Lead sponsor: CRG UZ Brussel
Sponsor class: OTHER
First posted: 2023-02-28
Enrollment: 1050
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 48
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients at high-risk of developing PE and planned to undergo ART:

* Oocyte recipients: patients are planned to undergo a transfer of an embryo conceived with a donor oocyte
* PCOS patients: patients diagnosed with polycystic ovary syndrome (Rotterdam criteria) and planned to undergo a IVF/ICSI or IVM treatment

Brief summary: The overarching goal of the project is to unravel PE etiopathogenesis in high-risk patients (PCOS patients and oocyte acceptors) after assisted reproductive technology (ART) to individualize prenatal care following ART and to determine potential targets for new PE prevention options decreasing the morbidity/mortality caused by this pathology. More specifically, the following objectives/work packages (WPs) are put forward:

* WP1 - PRECONCEPTION: Identify preconceptional maternal characteristics associated with in-creased risk of PE in ART patients (1a) and investigate the potential role of the endometrium prior to pregnancy (1b).
* WP2 - DURING PREGNANCY: Evaluate the Fetal Medicine Foundation's (FMF) first trimester PE screening in selected high-risk groups post ART to explore the clinical benefit in this specific context (2a) and investigate the association between parameters during the pregnancy and PE development post-ART.
* WP3 - AT DELIVERY: Identifying placental molecular pathways associated with PE post-ART.

Detailed description: Background:

Pre-eclampsia (PE) is a multisystemic syndrome occurring in 4-5% of pregnant women. It is defined by a new-onset hypertension (HT) developing after 20 weeks of gestation in combination with one of the following entities: proteinuria, maternal organ dysfunction and/or uteroplacental insufficiency. The vicious circle of the syndrome can end up in life-threatening complications for mother and child and, today, the only treatment of cure is the induction of delivery. Furthermore, besides the problems in the acute phase of the disease, women who experienced PE have been shown to have an increased lifetime risk of developing cardiovascular disease (CVD) and chronic kidney disease, while the children carry the consequences of their prematurity and, often following intra-uterine growth restriction, also seem to be more prone to develop metabolic disturbances like diabetes, HT and CVD later in life. Research, including data publishes by my own research group, shows that the risk of PE development in subfertile patients undergoing assisted reproductive technology (ART), is more than doubled, with incidences between 8-12%.

ART includes in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), using autologous or heterologous gametes, followed by fresh or frozen embryo transfer. The increased risk of PE within this population has mainly been attributed to known maternal PE risk factors associated with ART like increased maternal age, nulliparity and metabolic disturbances e.g. in patients with polycystic ovary syndrome (PCOS). Recent studies however have shown that ART is an independent risk factor of PE. More specifically, a higher PE incidence is consistently observed when patients have a frozen embryo transfer (FET) in an artificially prepared cycle. Unlike in a natural cycle in which ovulation occurs, an artificial cycle is characterized by the absence of ovulation as the luteal phase is induced by exogenous progesterone administration. It has been put forward that the absence of the corpus luteum, producing vasoactive and angiogenic substances (e.g. VEG-F, relaxin) and thereby orchestrating a correct placental development, could be held responsible for this observation. Other high risk ART patients are recipients of heterologous oocytes (i.e. oocyte recipients) potentially due to immunological conflicts.

In 2016, the ASPRE trial published their results evaluating a new first trimester screening tool developed by the fetal medicine foundation (FMF). This algorithm takes into account a limited number of anamnestic maternal characteristics, maternal blood pressure, the measurement of placental growth factor (PlGF) as a serum biomarker and the ultrasonographic measurement of the pulsatility index of the uterine artery. When an increased risk of PE had been detected (\>1/100), aspirin daily is given, starting before 16 weeks' of gestation.

As of May 2021, the FMF first trimester screening for PE is offered in the Brussels IVF fertility clinic to all the above-described high-risk patients pregnant following ART (PCOS and oocyte recipients included). Preliminary data confirm a high incidence of positive screening with an overall risk of 18%, reaching upto 27% in oocyte recipients (compared to the reported 10% in the general population following spontaneous conception). To the best of our knowledge, the applicability of the screening tool and aspirin administration for PE prevention has never been specifically evaluated post-ART. PE etiopathogenesis is complex and the exact molecular causative processes are still being unraveled. PE has a wide range of clinical presentations and it is currently unknown what drives these differences. Of critical importance for instance is the difference between early onset pre-eclampsia (EOPE), defined as PE occurring before 34 weeks of gestation and late onset pre-eclampsia (LOPE), defined as PE occurring at or after 34 weeks of gestation. In EOPE, which is mainly a placental disease, the impaired invasion of the spiral arteries by the extravillous cytotrofoblast cells has been put forward as the key pathophysiological component. This in contrary to LOPE, which is seen as a maternal disease, where there is a discrepancy between fetal growth, aging of the placenta an the maternal supply and cardiovascular reserve. Further, single-cell RNA sequencing on placentas confirmed the extensive different expressed genes between EOPE and LOPE. Also, the role of different serum markers (PlGF, sFLT-1, VEGF, leptin, annexin...) have been studied, but their contribution to EOPE and LOPE still remains unclear.

Lastly, very limited but intriguing research data suggest that the preconceptional endometrium could be implicated in PE development during pregnancy, with the focus on impaired decidualization and its role in PE origin. Given the differences in patient characteristics between the above-mentioned ART subgroups at risk for PE, our research team expects their PE-etiopathogenesis to be diverse. Though the multidisciplinary approach of this project, both on a clinical and fundamental research level, we hope to unravel pre-eclampsia, a multifactorial disease, and this in specific relation to different ART high-risk groups. This way, ultimately, the results will point towards targets for prevention and treatment of PE following ART and will contribute to a decrease in the morbidity and mortality associated with this devastating disease, for which, currently, no cure but termination of the pregnancy is available.

Hypothesis:

Work package 1a: there is a significant difference in preconceptional maternal characteristics between ART patients screening positive/developing PE and ART patients screening negative/not developing PE and these identified risk factors are specific for each ART subgroup.

Work package 1b: preconceptionally harvested endometrial tissue/stromal cells/organoids harbor significant differences in function of the subsequent (i.e. during pregnancy) negative or positive PE screening, PE development and specific high-risk ART group.

Work package 2a: the incidence of a positive screening/PE development (EOPE vs. LOPE) differs significantly among different ART groups.

Work package 2b: parameters during the pregnancy (blood pressure, biomarkers in the blood, ultrasound, nutritional and cardiac parameters) are significantly different between ART patients screening positive/developing PE and these identified parameters are specific for each ART subgroup.

Work package 3: placental tissue, membranes, cord tissue and cord blood harbor significant differences in expressed molecular pathways depending on negative or positive PE screening, PE development or not and are specific for the high-risk ART group.

Experimental design:

Prospective interventional cohort study without the use of a product nor medical device.

Methodology:

The study population will be subdivided into two different patient groups. Patients will be asked to participate to the study when they are planning to undergo ART and are (already prior to the start of their treatment) suspected to be at higher risk for the development PE after achieving pregnancy:

* Group 1 will include oocyte recipients as the use of donor oocytes predisposes them to a potential immunological conflict during pregnancy contributing to PE development
* Group 2 will include PCOS patients as endocrine and metabolic abnormalities predispose them to an abnormal trophoblast invasion contributing to PE development Work package 1a: evaluation of maternal baseline characteristics, laboratory studies, ultrasound examination, cardiac and nutritional work-up.

Work package 1b: harvesting and biobanking of preconceptional endometrium during the luteal phase of a preparative non-conceptional test-ART cycle (MOCK cycle). Depending on the outcome of the pregnancy, tissue can be thawed and used for basic research experiments (stromal cell lines, organoids, decidualization experiments, implantation experiments).

Work package 2a: patients are screened between 11- and 14-weeks' gestation using the FMF PE screening algorithm (routine care at our center). When patients are determined to be at high-risk of PE development (\>1/100), they are advised to take aspirin (160 mg daily) until 36 weeks' gestation.

Work package 2b: patients will be followed up at different time points during their pregnancy (7, 12, 20, 28, 36 weeks' gestation) using urine sampling, blood analysis, blood pressure measurement, cardiac and nutritional work-up and ultrasound evaluation.

Work package 3: collection of placental tissue, membranes, umbilical cord tissue and cord blood at time of delivery for basic research analysis. Evaluation of different molecular pathways and expressed genes between no PE, EOPE and LOPE and this in specific relation to the different high-risk groups.

Eligibility criteria: Inclusion Criteria:

* First time oocyte acceptors Or Nulliparous PCOS patients undergoing ART (IVF/ICSI)
* Criteria for PCOS: two out of the three following criteria must be present:

  1. Oligo-or anovulation: a menstrual cycle \>35 days
  2. Hyperandrogenism:

     * Clinically: the presence of hirsutism and/ or severe acne in combination with alopecia confirmed hyperandrogenism Or
     * Biochemically: serum total testosterone \>52 ng/dl or calculated free testosterone \>0,64 ng/dl
  3. Polycystic ovaries:

     * Follicle number per ovary (FNPO) ≥ 12 on both ovaries Or
     * Ovarian volume ≥ 10 ml in both ovaries Or
     * One ovary with ≥ 20 follicles (Using endovaginal US transducers with a frequency bandwidth that includes 8 MHz) Or
     * AMH ≥ 4,9 ng/ml

Exclusion Criteria:

* Known essential hypertension or development of a new-onset hypertension before 20 weeks' gestation

  * Hypertension is defined as a systolic blood pressure ≥ 140 or a diastolic blood pressure ≥ 90 on two separate measurements with at least 20 minutes in between, taken when the patients is in a seated position Or
  * The patient is known with hypertension, diagnosed by a certified doctor
* Known diabetes type 1 or 2 before pregnancy

  * Diagnosis of diabetes is confirmed when one of the following is present:

    * Fasting glucose ≥ 126 mg/dl
    * A 2-hour plasma glucose level ≥ 200 mg/dL during a 75-g oral glucose tolerance test Or
  * The patient is known with diabetes (type 1 or 2), diagnosed by a certified doctor
* Thyroid dysfunction not under control with medication:

  * Hyperthyroidism, the diagnoses is made when:
* Peripheral blood TSH \<0,5 mIU/L and fT4 \>1,9 ng/dl Or
* When the patient is known with hyperthyroidism diagnosed by a certified physician

  * Hypothyroidism, the diagnosis is made when:

    * Peripheral blood TSH \>5 mIU/L and fT4 \<0,7 ng/dl Or
    * When the patient is known with hypothyroidism diagnosed by a certified physician
* Other endocrinological disorder (including Cushing syndrome, Adrenal insufficiency, acromegaly): for diagnosis we will trust the opinion of the certified endocrinologist
* Cardiovascular diseases (including coronary artery disease, arrhythmia, heart valve disease and heart failure): for diagnosis we will trust the opinion of the certified cardiologist
* Renal disease/insufficiency: for diagnosis we will trust the opinion of the certified nephrologist
* Systemic lupus erythematosus: for diagnosis we will trust the opinion of the certified internal medicine doctor
* Antiphospholipid syndrome: for diagnosis we will trust the opinion of the certified internal medicine doctor
* Liver dysfunction/disease: for diagnosis we will trust the opinion of the certified gastroenterologist
* History of prior pre-eclampsia
* Women pregnant with a fetus with known abnormalities such chromosomal anomalies, structural deformities of limbs or organs or any other prebirth diagnosed syndromes or defects
* Multiple pregnancy

Primary outcomes:
measure: BMI (kg/m2)
timeFrame: 1 year
measure: Total energy expenditure (kcal/day)
timeFrame: 1 year
measure: number of laps of 6MWT (number)
timeFrame: 1 year
measure: Saturation beginning and end of 6MWT (%)
timeFrame: 1 year
measure: pulse beginning and end of 6MWT
timeFrame: 1 year
measure: Effective maximal handgrip strength (KPa)
timeFrame: 1 year
measure: Time until 50% of effective handgrip strenght (s)
timeFrame: 1 year
measure: IVSd (mm)
timeFrame: 1 year
measure: PWTd (mm)
timeFrame: 1 year
measure: LVEDD (mm)
timeFrame: 1 year
measure: IVSs (mm)
timeFrame: 1 year
measure: PWTs (mm)
timeFrame: 1 year
measure: LVESD (mm)
timeFrame: 1 year
measure: LV mass (indexed) mg/m2
timeFrame: 1 year
measure: LVEF (visual, manual modified Simpson's biplane, auto-EF) (%)
timeFrame: 1 year
measure: LV GLS (LV MW) (-%)
timeFrame: 1 year
measure: E-wave velocity (cm/s)
timeFrame: 1 year
measure: A-wave velocity (cm/s)
timeFrame: 1 year
measure: Deceleration time (ms)
timeFrame: 1 year
measure: E/A ratio
timeFrame: 1 year
measure: Septal wall e' (cm/s)
timeFrame: 1 year
measure: Lateral wall e' (cm/s)
timeFrame: 1 year
measure: E/e' ratio
timeFrame: 1 year
measure: Septal e'/lateral e' ratio
timeFrame: 1 year
measure: LA AP diameters (mm)
timeFrame: 1 year
measure: LAESVi (mL/M2)
timeFrame: 1 year
measure: La strain (-%)
timeFrame: 1 year
measure: TAPSE (mm)
timeFrame: 1 year
measure: RV s' (cm)
timeFrame: 1 year
measure: RV GLS (RV MW) (-%)
timeFrame: 1 year
measure: systolic, diastolic bloodpressure and mean arterial pressure (mmHg)
timeFrame: 1 year
measure: Pulsatility index of the uterine artery
timeFrame: 1 year
measure: (sub)endometrial flow (1,2,3)
timeFrame: 1 year
measure: PRL mRNA expression
timeFrame: 3 months
measure: PRL production (ng/ml)
timeFrame: 3 months
measure: IGFBP1 mRNA expression
timeFrame: 3 months
measure: IGFBP1 (pg/ml)
timeFrame: 3 months
measure: PlGF (pg/ml)
timeFrame: 3 months
measure: sFLT1 (pg/ml)
timeFrame: 3 months
measure: sENG (ng/ml)
timeFrame: 3 months
measure: Incidence of positive PE screening (%)
timeFrame: 6 months
measure: Estimated fetal weight (g)
timeFrame: 1 year
measure: PI umbilical artery
timeFrame: 1 year
measure: PI uterine artery
timeFrame: 1 year
measure: gestational age at diagnoses PE (weeks)
timeFrame: 1 year
measure: incidence of PE (%)
timeFrame: 1 year
measure: severity of PE (mild/severe)
timeFrame: 1 year
measure: gestational age at delivery (weeks)
timeFrame: 1 year
measure: birth weight (grams)
timeFrame: 1 year
measure: APGAR scores of baby after 1, 5 and 10 minutes (1-10)
timeFrame: 1 year
measure: different expressed genes (DEGs) of placenta's
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Brussels
country: Belgium
facility: Brussels IVF
Study officials:
affiliation: Medical director Brussels IVF
name: Shari Mackens, PhD, MD
role: PRINCIPAL_INVESTIGATOR
References: